Preinterventional pan-immune-inflammation value as a tool to predict postcontrast acute kidney injury among acute coronary syndrome patients implanted drug-eluting stents: a retrospective observational study

References

• Bhatt DL, Lopes RD, Harrington RA. Diagnosis and treatment of acute coronary syndromes: a review. JAMA. 2022;327(7):662–675. doi: 10.1001/jama.2022.0358.
   PubMed Web of Science ®Google Scholar
• Cuddy E, Robertson S, Cross S, et al. Risks of coronary angiography. Lancet. 2005;366(9499):1825. doi: 10.1016/S0140-6736(05)67729-X.
   PubMed Web of Science ®Google Scholar
• James MT, Ghali WA, Tonelli M, et al. Acute kidney injury following coronary angiography is associated with a long-term decline in kidney function. Kidney Int. 2010;78(8):803–809. doi: 10.1038/ki.2010.258.
   PubMed Web of Science ®Google Scholar
• Watabe H, Sato A, Hoshi T, et al. Association of contrast-induced acute kidney injury with long-term cardiovascular events in acute coronary syndrome patients with chronic kidney disease undergoing emergent percutaneous coronary intervention. Int J Cardiol. 2014;174(1):57–63. doi: 10.1016/j.ijcard.2014.03.146.
   PubMed Web of Science ®Google Scholar
• Azzalini L, Spagnoli V, Ly HQ. Contrast-Induced nephropathy: from pathophysiology to preventive strategies. Can J Cardiol. 2016;32(2):247–255. doi: 10.1016/j.cjca.2015.05.013.
   PubMed Web of Science ®Google Scholar
• Fucà G, Guarini V, Antoniotti C, et al. The pan-immune-inflammation value is a new prognostic biomarker in metastatic colorectal cancer: results from a pooled-analysis of the valentino and TRIBE first-line trials. Br J Cancer. 2020;123(3):403–409. doi: 10.1038/s41416-020-0894-7.
   PubMed Web of Science ®Google Scholar
• Baba Y, Nakagawa S, Toihata T, et al. Pan-immune-inflammation value and prognosis in patients with esophageal cancer. Ann Surg Open. 2021;3(1):e113. doi: 10.1097/AS9.0000000000000113.
   PubMedGoogle Scholar
• Qi X, Qiao B, Song T, et al. Clinical utility of the pan-immune-inflammation value in breast cancer patients. Front Oncol. 2023;13:1223786. doi: 10.3389/fonc.2023.1223786.
   PubMedGoogle Scholar
• Murat B, Murat S, Ozgeyik M, et al. Comparison of pan-immune-inflammation value with other inflammation markers of long-term survival after ST-segment elevation myocardial infarction. Eur J Clin Invest. 2023;53(1):e13872.
   PubMed Web of Science ®Google Scholar
• Liu Y, Liu J, Liu L, et al. Association of systemic inflammatory response index and pan-immune-inflammation-value with long-term adverse cardiovascular events in ST-Segment elevation myocardial infarction patients after primary percutaneous coronary intervention. J Inflamm Res. 2023;16:3437–3454. doi: 10.2147/JIR.S421491.
   PubMed Web of Science ®Google Scholar
• Bayramoğlu A, Hidayet Ş. Association between pan-immune-inflammation value and no-reflow in patients with ST elevation myocardial infarction undergoing percutaneous coronary intervention. Scand J Clin Lab Invest. 2023;83(6):384–389. doi: 10.1080/00365513.2023.2241131.
   PubMed Web of Science ®Google Scholar
• Inan D, Erdogan A, Pay L, et al. The prognostic impact of inflammation in patients with decompensated acute heart failure, as assessed using the pan-immune inflammation value (PIV). Scand J Clin Lab Invest. 2023;83(6):371–378. doi: 10.1080/00365513.2023.2233890.
   PubMed Web of Science ®Google Scholar
• Byrne RA, Rossello X, Coughlan JJ, ESC Scientific Document Group., et al. 2023 ESC guidelines for the management of acute coronary syndromes. Eur Heart J. 2023;44(38):3720–3826. doi: 10.1093/eurheartj/ehad191.
   PubMed Web of Science ®Google Scholar
• Levey AS, Coresh J, Greene T, Chronic Kidney Disease Epidemiology Collaboration., et al. Expressing the modification of diet in renal disease study equation for estimating glomerular filtration rate with standardized serum creatinine values. Clin Chem. 2007;53(4):766–772. doi: 10.1373/clinchem.2006.077180.
   PubMed Web of Science ®Google Scholar
• Vemireddy L, Bansal S. Contrast-Associated acute kidney injury: definitions, epidemiology, pathophysiology, and implications. Interv Cardiol Clin. 2023;12(4):489–498. doi: 10.1016/j.iccl.2023.06.007.
   PubMedGoogle Scholar
• Seeliger E, Sendeski M, Rihal CS, et al. Contrast-induced kidney injury: mechanisms, risk factors, and prevention. Eur Heart J. 2012;33(16):2007–2015. doi: 10.1093/eurheartj/ehr494.
   PubMed Web of Science ®Google Scholar
• Butt K, D'Souza J, Yuan C, et al. Correlation of the neutrophil-to-lymphocyte ratio (NLR) and platelet-to- lymphocyte ratio (PLR) with contrast-Induced nephropathy in patients with acute coronary syndrome undergoing percutaneous coronary interventions. Cureus. 2020;12(12):e11879. doi: 10.7759/cureus.11879.
   PubMed Web of Science ®Google Scholar
• Kocas C, Yildiz A, Abaci O, et al. Platelet-to-lymphocyte ratio predicts contrast-Induced nephropathy in patients with non-ST-Segment elevation acute coronary syndrome. Angiology. 2015;66(10):964–968. doi: 10.1177/0003319715578057.
   PubMed Web of Science ®Google Scholar
• Sun XP, Li J, Zhu WW, et al. Platelet to lymphocyte ratio predicts contrast-Induced nephropathy in patients with ST-Segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Angiology. 2018;69(1):71–78. doi: 10.1177/0003319717707410.
   PubMed Web of Science ®Google Scholar
• Zorlu C, Koseoglu C. Comparison of the relationship between inflammatory markers and contrast-Induced nephropathy in patients with acute coronary syndrome after coronary angiography. Angiology. 2020;71(3):249–255. doi: 10.1177/0003319719892160.
   PubMed Web of Science ®Google Scholar
• Şen F, Kurtul A, Bekler Ö. Pan-Immune-inflammation value is independently correlated to impaired coronary flow after primary PCI in patients with ST-Segment elevation myocardial infarction. Am J Cardiol. 2024;211:153–159. doi: 10.1016/j.amjcard.2023.10.088.
   PubMed Web of Science ®Google Scholar
• Cetinkaya Z, Kelesoglu S. The role of pan-immune-inflammation value in predicting contrast-Induced nephropathy development in patients undergoing percutaneous coronary intervention due to NSTEMI. Angiology. 2023;33197231211107. Oct 30:33197231211107. Epub ahead of print. doi: 10.1177/00033197231211107.
   PubMedGoogle Scholar
• Coutinho Cruz M, Ilhão Moreira R, Abreu A, et al. The smoker’s paradox in acute coronary syndrome: is it real? Rev Port Cardiol (Engl Ed). 2018;37(10):847–855. doi: 10.1016/j.repc.2017.12.005.
   PubMed Web of Science ®Google Scholar
• Weisz G, Cox DA, Garcia E, et al. Impact of smoking status on outcomes of primary coronary intervention for acute myocardial infarction–the smoker’s paradox revisited. Am Heart J. 2005;150(2):358–364. doi: 10.1016/j.ahj.2004.01.032.
   PubMed Web of Science ®Google Scholar
• Robertson JO, Ebrahimi R, Lansky AJ, et al. Impact of cigarette smoking on extent of coronary artery disease and prognosis of patients with non-ST-segment elevation acute coronary syndromes: an analysis from the ACUITY trial (acute catheterization and urgent intervention triage strategy). JACC Cardiovasc Interv. 2014;7(4):372–379. doi: 10.1016/j.jcin.2013.11.017.
   PubMed Web of Science ®Google Scholar
• Amor-Salamanca A, Devesa-Cordero C, Cuesta-Díaz A, et al. La paradoja del tabaco en el yndrome coronario agudo sin elevación del ST [smoking paradox in acute coronary syndrome without ST-segment elevation]. Med Clin (Barc). 2011;136(4):144–148. doi: 10.1016/j.medcli.2010.01.039.
   PubMedGoogle Scholar
• Aune E, Røislien J, Mathisen M, et al. The “smoker’s paradox” in patients with acute coronary syndrome: a systematic review. BMC Med. 2011;9(1):97. doi: 10.1186/1741-7015-9-97.
   PubMedGoogle Scholar
• Symons R, Masci PG, Francone M, et al. Impact of active smoking on myocardial infarction severity in reperfused ST-segment elevation myocardial infarction patients: the smoker’s paradox revisited. Eur Heart J. 2016;37(36):2756–2764. doi: 10.1093/eurheartj/ehv738.
   PubMed Web of Science ®Google Scholar